TFA
LGND icon

Transamerica Financial Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Transamerica Financial Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3K Hold
80
– – ﹤0.01% 818
2026
Q1 		$16K Hold
80
– – ﹤0.01% 840
2025
Q4 		$15.1K Hold
80
– – ﹤0.01% 768
2025
Q3 		$14.2K Buy
+80
New +$11.9K ﹤0.01% 668

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Transamerica Financial Advisors's LGND Position: Q2 2026 in Review

Transamerica Financial Advisors held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 80 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #818.

Transamerica Financial Advisors first reported a position in LGND in Q3 2025 and has held it in 4 quarters since. 415 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Transamerica Financial Advisors held 80 shares of Ligand Pharmaceuticals worth $25.3K as of Q2 2026.
  • Transamerica Financial Advisors left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #818 holding.
  • Transamerica Financial Advisors first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 415 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.